FIRST Trial: Lenalidomide/Dexamethasone versus Melphalan/Prednisone/Thalidomide in Newly Diagnosed Multiple Myeloma


FIRST Trial: Lenalidomide/Dexamethasone versus Melphalan/Prednisone/Thalidomide in Newly Diagnosed Multiple Myeloma
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Sagar Lonial, MD (1/22/14)
Facon T et al. Initial Phase 3 results of the First (Frontline Investigation of Lenalidomide + Dexamethasone versus Standard Thalidomide) trial (MM-020/IFM 07 01) in newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for stem cell transplantation (SCT). Proc ASH 2013;Abstract 2.

Dr Lonial is Professor, Vice Chair of Clinical Affairs and Director of Translational Research for the B-Cell Malignancy Program in the Department of Hematology and Medical Oncology at the Emory University School of Medicine Winship Cancer Institute in Atlanta, Georgia.